Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.

ABSTRACT: In early symptomatic COVID-19 treatment, high dose oral favipiravir did not accelerate viral clearance.

Background

Favipiravir, an anti-influenza drug, has in vitro antiviral activity against SARS-CoV-2. Clinical trial evidence to date is inconclusive. Favipiravir has been recommended for the treatment of COVID-19 in some countries.

Methods

In a multicentre open-label, randomised, controlled, adaptive platform trial, low-risk adult patients with early symptomatic COVID-19 were randomised to one of ten treatment arms including high dose oral favipiravir (3.6g on day 0 followed by 1.6g daily to complete 7 days treatment) or no study drug. The primary outcome was the rate of viral clearance (derived under a linear mixed-effects model from the daily log₁₀ viral densiti

SUBMITTER: Luvira V 

PROVIDER: S-EPMC10789040 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature